Update in XXXX : Novel Agents and Targeted Therapy.

@entity1 @entity5 @entity900 @entity189 @entity136 @entity150 @entity4149 @entity902
UNASSIGNED: @entity189 ( @entity189 ) is a chemosensitive disease with high response rates to @entity902 -based combination chemotherapy in locally advanced or advanced disease. However, de novo or emergence of @entity900 -resistance limits the duration of response, @entity1 are frequently ineligible for @entity900 , and therapies tested thus far have minimal activity as second-line therapy. The first wave of clinical trials of novel agents and targeted therapy have modestly advanced the field and laid the foundations for future studies. These trials include the deployment of monoclonal antibodies and @entity4149 kinase inhibitors that target mediators of angiogenesis and growth receptors. Novel cytotoxic agents have also been tested as single-agents in the second-line setting and together with the first-line combination of @entity136 with @entity900 . To date, these novel agents have yet to demonstrate the ability to substantially improve the overall survival of @entity1 with @entity150 . Comparative trials of chemotherapy with or without a novel agent are ongoing and have the potential to improve upon current standard therapy. Moreover, state-of-the-art technologies have been developed that will likely identify the molecular alterations which drive both @entity189 and @entity902 -resistance and in turn provide opportunities for drug development. The latter includes an interrogation of microRNAs and the integrated study of genetic mutations in extreme phenotypes of the disease. In essence, this ongoing work paired with physician and @entity1 commitments to clinical trial participation will ultimately lead to advances in the care of @entity1 with @entity5 .
